查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1632628

体内 CRO 市场规模、份额、趋势分析报告：按模型类型、按模式、按适应症、按 GLP 类型、按地区、细分市场预测，2025-2030 年

In Vivo CRO Market Size, Share & Trends Analysis Report By Model Type (Rodent Based, Non-Rodent Based), By Modality (Small Molecule, Large Molecule), By Indication, By GLP Type, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

体内 CRO 市场成长与趋势：

根据 Grand View Research, Inc. 的最新报告，预计到 2030 年，全球 In Vivo CRO 市场规模将达到 79.6 亿美元，2025 年至 2030 年复合年增长率为 8.13%。

新兴国家医药市场的成长、对多种体内细胞疗法的强劲需求、材料科学的快速发展以及药物-器械组合的复杂性正在推动该地区的服务需求。此外，体内临床前和临床研究的增加、监管部门的核准、市场参与企业服务的扩展以及各种疾病负担都对市场收益做出了贡献。此外，新兴经济体增加低成本临床前和临床服务外包是支持体内 CRO 市场成长的关键因素之一。

同样，越来越多的药品境外外包到新兴国家也创造了庞大的市场需求。已开发国家的预算审查、价格压力和报销制度的变化是预计印度和中国等新兴国家药品赞助商更多采用成本控制措施的一些关键因素。在新兴国家，将临床前体内服务等开发服务外包给合约服务供应商预计将增加对品质保证和监管服务的需求，从而促进对体内外包服务的需求增加。 FDA核准的严格流程以及欧盟地区的监管变化预计将使欧洲的核准流程复杂化。这些都是促使製药公司境外外包到新兴国家的主要因素。

COVID-19 大流行最初对临床试验行业产生了负面影响，但体内 CRO 市场也是如此。生物製药产业将重点转向开发针对 COVID-19 的疫苗和治疗方法，这产生了意想不到的后果，可能会扰乱其他疾病的临床试验。细胞和基因治疗行业的公司面临的主要挑战之一是无法在所需的临床试验地点及时为患者提供治疗。此外，基于细胞的疗法的提供在大流行后带来了一些挑战。由于担心 SARS-CoV-2 传播，尤其是针对弱势群体，医院对提供细胞治疗服务犹豫不决。由于封锁和旅行禁令，患者无法前往细胞治疗中心。

此外，主要参与企业正在参与併购、伙伴关係、协议、联盟和服务发布等策略，以扩大其全球足迹和服务/产品系列。例如，2023年4月，PsychoGenics, Inc.宣布推出eCube，这是一个药理学脑电图平台，旨在增强表型药物发现。同样，2023年2月，百奥赛图宣布推出Nano 100计划，开发100多种针对特定标靶的全人奈米抗体药物。这项工作将百奥赛图专有的 RenNano（一种能够产生完全人类奈米抗体的小鼠模型）与先进的体外和体内抗体筛检平台结合。透过利用这些整合技术，百奥赛图有望促进全人类奈米抗体药物的广泛开发。

体内 CRO 市场报告亮点

  • 囓齿类动物的需求量一直很大，因为它们在基因上​​与人类相似。由于其体型小、生命週期短、易于维护和遗传资源丰富，它也是体内 CRO 研究最普遍的动物物种。
  • 小分子领域在体内 CRO 市场中占据主导地位。这种增长是由候选药物开发中对小分子的需求所推动的。此外，小分子在小剂量下具有较高的治疗功效，这正在推动该领域的成长。
  • 肿瘤学领域在 In Vivo CRO 的全球市场中占据主导地位，2024 年占 29.02% 的销售份额。成长的主要驱动因素包括癌症负担的增加、对新基因疗法的需求激增以及癌症免疫疗法的临床前测试。据美国基因与细胞治疗协会称，大约 97% 的 CAR T 细胞疗法正在针对癌症适应症进行开发。
  • 由于各种针对脑部疾病的模型为基础的临床实验药物的功效，中枢神经系统疾病领域预计将出现最快的成长。
  • 由于根据特定指南进行的标准化测试的增加，GLP 毒理学领域在 2024 年以最大的收益占有率占据市场主导地位。
  • 2024年，北美在体内CRO市场中占据最大收益占有率，达到50.0%。该地区的成长归因于成熟市场参与者的存在、各种疾病负担的增加以及该地区对 CRO 的需求不断增长。其他成长要素包括研发活动、临床前试验和市场参与者创新的增加。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章体内 CRO 市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 体内 CRO 市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第四章体内 CRO 市场：模态估计与趋势分析

  • 在 Vivo CRO 市场中，按模式：细分仪表板
  • Vivo CRO 市场按模式：波动分析
  • 按方式划分，2018-2030
  • 小分子
    • 小分子市场，2018-2030
  • 高分子
    • 高分子市场，2018-2030
    • 细胞/基因治疗
    • RNA疗法
    • 其他的

第五章体内CRO市场：模型类型估计与趋势分析

  • 在 Vivo CRO 市场中，按模型类型：细分仪表板
  • 在 Vivo CRO 市场中，依模型类型：变异分析
  • 按车型类型，2018-2030
  • 基于囓齿动物的
    • 囓齿动物市场，2018-2030
    • 大鼠模型
    • 小鼠模型
    • 其他的
  • 不囓齿动物为基础
    • 非囓齿动物市场，2018-2030

第六章体内CRO市场：适应症估计与趋势分析

  • 在 Vivo CRO 市场中，按指示：细分仪表板
  • 在 Vivo CRO 市场中，依适应症分类：变异分析
  • 按迹象显示，2018-2030
  • 自体免疫/发炎性疾病
    • 自体免疫疾病/发炎性疾病市场，2018-2030
    • 类风湿性关节炎
    • 多发性硬化症
    • 骨关节炎
    • 大肠激躁症
    • 其他的
  • 疼痛管理
    • 疼痛管理市场，2018-2030
    • 慢性疼痛
    • 急性疼痛
  • 肿瘤学
    • 肿瘤市场，2018-2030
    • 血癌
    • 固态肿瘤
    • 其他的
  • 中枢神经系统症状
    • 中枢神经系统疾病市场，2018-2030
    • 癫痫
    • 帕金森氏症
    • 亨丁顿舞蹈症
    • 中风
    • 肌肉萎缩症
    • 阿兹海默症
    • 脑外伤
    • 肌萎缩侧索硬化症 (ALS)
    • 脊髓性肌肉萎缩症
    • 肌肉再生
    • 其他神经发育障碍
  • 糖尿病
    • 糖尿病市场，2018-2030
  • 肥胖
    • 肥胖市场，2018-2030
  • 其他的
    • 其他市场，2018-2030

第七章体内CRO市场：GLP类型估计与趋势分析

  • 在体内 CRO 市场，按 GLP 类型：细分仪表板
  • Vivo CRO 市场，依 GLP 类型：波动分析
  • 依 GLP 类型，2018-2030
  • 非GLP
    • 非 GLP 市场，2018-2030
  • GLP毒理学
    • 基于 GLP 毒理学的市场，2018-2030

第八章体内 CRO 市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场简介
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 市场参与企业分类
  • 2023/24 年企业市场占有率分析
  • 公司简介
    • IQVIA Inc
    • Crown Bioscience
    • Taconic Biosciences, Inc.
    • PsychoGenics Inc.
    • Evotec
    • Janvier Labs
    • Biocytogen
    • GemPharmatech
    • Charles River Laboratories
    • Icon Plc
    • Labcorp Drug Development
    • Parexel International Corporation
    • SMO Clinical Research（I）Pvt Ltd

第10章主要建议

Product Code: GVR-1-68038-011-8

In Vivo CRO Market Growth & Trends:

The global in vivo CRO market size is estimated to reach USD 7.96 billion by 2030, expanding at a CAGR of 8.13% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the pharmaceutical market in emerging countries, along with strong demand for numerous in vivo cell therapies, rapid advancements in material sciences, and complexities of drug-device combinations, has led to the demand for services in the region. Additionally, rising in vivo preclinical and clinical research, regulatory approval, expanding services by market players, and the burden of different diseases contribute to market earnings. Also, increasing outsourcing of preclinical and clinical services across developing economies at a lower cost is one of the major factors supporting the growth of in vivo CRO market.

Likewise, the increase in offshoring drugs to emerging economies has created immense demand for the market. Budget scrutiny in developed countries, pricing pressure, and changes in reimbursement schemes are some of the major factors anticipated to increase the adoption of cost-containment measures by drug sponsors in emerging countries such as India and China. Outsourcing development services such as preclinical in vivo services to contract service providers in emerging countries is expected to boost the demand for quality assurance & regulatory affairs services, thereby contributing to the rising demand for in vivo outsourced services. Stringent processes for FDA approval and regulatory changes in the EU region are expected to make the approval process in Europe complex. They are some of the major factors contributing to the offshoring of drug companies to emerging countries.

The COVID-19 pandemic has initially negatively impacted the clinical trials industry and the in vivo CRO market was no different! The shift in the focus of the biopharmaceutical industry on developing vaccines & therapies in response to COVID-19 has resulted in the unintended consequences of potentially disrupting clinical trials for other diseases. One of the key issues faced by companies operating in the cell and gene therapy industry is the untimely delivery of therapies to patients at required clinical sites. In addition, the administration of cell-based therapeutics poses several post-pandemic challenges. Hospitals have shown hesitation in offering cell therapy services owing to concerns over transmission of SARS-CoV-2, especially to vulnerable individuals. Patients have not been able to visit cell therapy centers either owing to the lockdowns or travel bans.

Furthermore, the key participants are engaged in strategies such as mergers & acquisitions, partnerships, agreements, collaborations, and service launches, among others, to expand their global footprints and service/product portfolio. For instance, in April 2023, PsychoGenics, Inc. announced the launch of eCube, a pharmaco-electroencephalography platform, to enhance phenotypic drug discovery. Similarly, in February 2023, Biocytogen recently introduced "the Nano 100 Project" to develop over 100 fully human nanobody drugs that target specific targets. This endeavor involves combining Biocytogen's proprietary RenNano, a mouse model capable of producing fully human nanobodies, with their advanced in vitro and in vivo antibody screening platforms. By leveraging these integrated technologies, Biocytogen is poised to facilitate the extensive development of fully human nanobody drugs.

In Vivo CRO Market Report Highlights:

  • The rodent-based segment held the largest revenue share of 81.95% owing to constant model demand as they are genetically similar to humans. Besides, their small size, short life cycle, ease of maintenance, and availability of genetic resources, make them the most prevalent species in in-vivo CRO research
  • The small molecule segment dominated the in vivo CRO market. The growth is attributed to the demand for small molecules in the development of drug candidates. In addition, the strong therapeutic effect of small molecules in a small dose is the key factor aiding segment growth
  • The oncology segment dominated the global in vivo CRO market and accounted for a revenue share of 29.02% in 2024, the key factors contributing to the growth include the growing burden of cancer, surging demand for new gene therapy, and preclinical studies for cancer immunotherapy. According to the American Society of Gene Cell Therapy, around 97% of CAR T-cell therapies are developed for cancer indications
  • The CNS conditions segment is anticipated to register the fastest growth, owing to the effectiveness of different model-based investigational compounds targeting brain diseases is expected to drive segment growth
  • The GLP toxicology segment dominated the market with the largest revenue share in 2024 owing to the increasing number of standardized studies conducted according to specific guidelines
  • North America held the largest revenue share of 50.0% in in-vivo CRO market in 2024. The growth in the region can be attributed to the presence of well-established market players, the increasing burden of different diseases, growing demand for CROs in the region. Other factors contributing to the growth are increased research and development activities, preclinical studies, and innovations of market players.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Modality
    • 1.2.2. Model Type
    • 1.2.3. Indication
    • 1.2.4. GLP Type
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Parent Market Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. In Vivo CRO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Changing regulatory landscape
      • 3.2.1.2. Increase in offshoring medical device manufacturing to emerging countries
      • 3.2.1.3. Rising demand for advanced products
      • 3.2.1.4. Implementation of international standards by contract manufacturers
      • 3.2.1.5. Rising price competition and requirement to reduce cost
      • 3.2.1.6. Increasing complexity concerning product design and engineering
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance Issues While Outsourcing
      • 3.2.2.2. Changing Scenarios in Developing Countries
      • 3.2.2.3. Regulatory And Legal Compliance
      • 3.2.2.4. Contractual Obligation
  • 3.3. In Vivo CRO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. In Vivo CRO Market: Modality Estimates & Trend Analysis

  • 4.1. In Vivo CRO Market, By Modality: Segment Dashboard
  • 4.2. In Vivo CRO Market, By Modality: Movement Analysis
  • 4.3. In Vivo CRO Market Estimates & Forecasts, By Modality, 2018 - 2030
  • 4.4. Small Molecule
    • 4.4.1. Small Molecule Market, 2018 to 2030 (USD Million)
  • 4.5. Large Molecule
    • 4.5.1. Large Molecule Market, 2018 to 2030 (USD Million)
    • 4.5.2. Cell & Gene Therapy
      • 4.5.2.1. Cell & Gene Therapy Market, 2018 to 2030 (USD Million)
      • 4.5.2.2. CAR T-cell therapies
        • 4.5.2.2.1. CAR T-Cell Therapies Market, 2018 to 2030 (USD Million)
      • 4.5.2.3. CAR-NK cell therapy
        • 4.5.2.3.1. CAR-NK Cell Therapy Market, 2018 to 2030 (USD Million)
      • 4.5.2.4. TCR-T cell therapy
        • 4.5.2.4.1. TCR-T Cell Therapy Market, 2018 to 2030 (USD Million)
      • 4.5.2.5. Other Cell & Gene Therapy
        • 4.5.2.5.1. Other Cell & Gene Therapy Market, 2018 to 2030 (USD Million)
    • 4.5.3. RNA Therapy
      • 4.5.3.1. RNA Therapy Market, 2018 to 2030 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1. Others Market, 2018 to 2030 (USD Million)

Chapter 5. In Vivo CRO Market: Model Type Estimates & Trend Analysis

  • 5.1. In Vivo CRO Market, By Model Type: Segment Dashboard
  • 5.2. In Vivo CRO Market, By Model Type: Movement Analysis
  • 5.3. In Vivo CRO Market Estimates & Forecasts, By Model Type, 2018 - 2030
  • 5.4. Rodent based
    • 5.4.1. Rodent based Market, 2018 to 2030 (USD Million)
    • 5.4.2. Rat Models
      • 5.4.2.1. Rat Models Market, 2018 to 2030 (USD Million)
    • 5.4.3. Mice Models
      • 5.4.3.1. Mice Models Market, 2018 to 2030 (USD Million)
    • 5.4.4. Others
      • 5.4.4.1. Others Market, 2018 to 2030 (USD Million)
  • 5.5. Non-Rodent based
    • 5.5.1. Non-Rodent based Market, 2018 to 2030 (USD Million)

Chapter 6. In Vivo CRO Market: Indication Estimates & Trend Analysis

  • 6.1. In Vivo CRO Market, By Indication: Segment Dashboard
  • 6.2. In Vivo CRO Market, By Indication: Movement Analysis
  • 6.3. In Vivo CRO Market Estimates & Forecasts, By Indication, 2018 - 2030
  • 6.4. Autoimmune/inflammation conditions
    • 6.4.1. Autoimmune/inflammation conditions Market, 2018 to 2030 (USD Million)
    • 6.4.2. Rheumatoid Arthritis
      • 6.4.2.1. Rheumatoid Arthritis Market, 2018 to 2030 (USD Million)
    • 6.4.3. Multiple Sclerosis
      • 6.4.3.1. Multiple Sclerosis Market, 2018 to 2030 (USD Million)
    • 6.4.4. Osteoarthritis
      • 6.4.4.1. Osteoarthritis Market, 2018 to 2030 (USD Million)
    • 6.4.5. Irritable Bowel Syndrome
      • 6.4.5.1. Irritable Bowel Syndrome Market, 2018 to 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Others Market, 2018 to 2030 (USD Million)
  • 6.5. Pain management
    • 6.5.1. Pain management Market, 2018 to 2030 (USD Million)
    • 6.5.2. Chronic pain
      • 6.5.2.1. Chronic pain Market, 2018 to 2030 (USD Million)
    • 6.5.3. Acute pain
      • 6.5.3.1. Acute pain Market, 2018 to 2030 (USD Million)
  • 6.6. Oncology
    • 6.6.1. Oncology Market, 2018 to 2030 (USD Million)
    • 6.6.2. Blood cancer
      • 6.6.2.1. Blood Cancer Market, 2018 to 2030 (USD Million)
    • 6.6.3. Solid tumor
      • 6.6.3.1. Solid Tumor Market, 2018 to 2030 (USD Million)
      • 6.6.3.2. Syngeneic model
        • 6.6.3.2.1. Syngeneic Model Market, 2018 to 2030 (USD Million)
      • 6.6.3.3. Patient derived xenograft
        • 6.6.3.3.1. Patient Derived Xenograft Market, 2018 to 2030 (USD Million)
      • 6.6.3.4. Xenograft
        • 6.6.3.4.1. Xenograft Market, 2018 to 2030 (USD Million)
    • 6.6.4. Others
      • 6.6.4.1. Others Market, 2018 to 2030 (USD Million)
  • 6.7. CNS Conditions
    • 6.7.1. CNS Conditions Market, 2018 to 2030 (USD Million)
    • 6.7.2. Epilepsy
      • 6.7.2.1. Epilepsy Market, 2018 to 2030 (USD Million)
    • 6.7.3. Parkinson's disease
      • 6.7.3.1. Parkinson's Disease Market, 2018 to 2030 (USD Million)
    • 6.7.4. Huntington's disease
      • 6.7.4.1. Huntington's Disease Market, 2018 to 2030 (USD Million)
    • 6.7.5. Stroke
      • 6.7.5.1. Stroke Market, 2018 to 2030 (USD Million)
    • 6.7.6. Muscular Dystrophy
      • 6.7.6.1. Muscular Dystrophy Market, 2018 to 2030 (USD Million)
    • 6.7.7. Alzheimer's Disease
      • 6.7.7.1. Alzheimer's Disease Market, 2018 to 2030 (USD Million)
    • 6.7.8. Traumatic brain injury
      • 6.7.8.1. Traumatic Brain Injury Market, 2018 to 2030 (USD Million)
    • 6.7.9. Amyotrophic lateral sclerosis (ALS)
      • 6.7.9.1. Amyotrophic Lateral Sclerosis (ALS) Market, 2018 to 2030 (USD Million)
    • 6.7.10. Spinal Muscular Atrophy
      • 6.7.10.1. Spinal Muscular Atrophy Market, 2018 to 2030 (USD Million)
    • 6.7.11. Muscle regeneration
      • 6.7.11.1. Muscle Regeneration Market, 2018 to 2030 (USD Million)
    • 6.7.12. Other Neurodevelopment Disorders
      • 6.7.12.1. Other Neurodevelopment Disorders Market, 2018 to 2030 (USD Million)
  • 6.8. Diabetes
    • 6.8.1. Diabetes Market, 2018 to 2030 (USD Million)
  • 6.9. Obesity
    • 6.9.1. Obesity Market, 2018 to 2030 (USD Million)
  • 6.10. Others
    • 6.10.1. Others Market, 2018 to 2030 (USD Million)

Chapter 7. In Vivo CRO Market: GLP Type Estimates & Trend Analysis

  • 7.1. In Vivo CRO Market, By GLP Type: Segment Dashboard
  • 7.2. In Vivo CRO Market, By GLP Type: Movement Analysis
  • 7.3. In Vivo CRO Market Estimates & Forecasts, By GLP Type, 2018 - 2030
  • 7.4. Non GLP
    • 7.4.1. Non GLP Market, 2018 to 2030 (USD Million)
  • 7.5. GLP Toxicology
    • 7.5.1. GLP Toxicology based Market, 2018 to 2030 (USD Million)

Chapter 8. In Vivo CRO Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. North America
    • 8.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.2. U.S
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Competitive Scenario
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Competitive Scenario
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Competitive Scenario
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Company Market Share Analysis, 2023/24
  • 9.3. Company Profiles
    • 9.3.1. IQVIA Inc
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Crown Bioscience
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Taconic Biosciences, Inc.
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. PsychoGenics Inc.
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Evotec
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Janvier Labs
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Biocytogen
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. GemPharmatech
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Charles River Laboratories
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Service Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Icon Plc
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Service Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. Labcorp Drug Development
      • 9.3.11.1. Company Overview
      • 9.3.11.2. Financial Performance
      • 9.3.11.3. Service Benchmarking
      • 9.3.11.4. Strategic Initiatives
    • 9.3.12. Parexel International Corporation
      • 9.3.12.1. Company Overview
      • 9.3.12.2. Financial Performance
      • 9.3.12.3. Service Benchmarking
      • 9.3.12.4. Strategic Initiatives
    • 9.3.13. SMO Clinical Research (I) Pvt Ltd
      • 9.3.13.1. Company Overview
      • 9.3.13.2. Financial Performance
      • 9.3.13.3. Service Benchmarking
      • 9.3.13.4. Strategic Initiatives

Chapter 10 Key Recommendations

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global In Vivo CRO Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 5 Global In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 6 Global In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 7 Global In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 8 North America In Vivo CRO Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 10 North America In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 11 North America In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 12 North America In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 14 U.S. In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 15 U.S. In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 16 U.S. In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 17 Canada In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 18 Canada In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 19 Canada In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 20 Canada In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 21 Mexico In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 22 Mexico In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 23 Mexico In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 24 Mexico In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 25 Europe In Vivo CRO Market, By Country, 2018 - 2030 (USD Million)
  • Table 26 Europe In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 27 Europe In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 28 Europe In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 29 Europe In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 30 UK In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 31 UK In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 32 UK In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 33 UK In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 34 Germany In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 35 Germany In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 36 Germany In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 37 Germany In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 38 France In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 39 France In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 40 France In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 41 France In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 42 Italy In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 43 Italy In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 44 Italy In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 45 Italy In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 46 Spain In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 47 Spain In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 48 Spain In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 49 Spain In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 50 Denmark In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 51 Denmark In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 52 Denmark In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 53 Denmark In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 54 Sweden In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 55 Sweden In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 56 Sweden In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 57 Sweden In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 58 Norway In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 59 Norway In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 60 Norway In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 61 Norway In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific In Vivo CRO Market, By Country, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 66 Asia Pacific In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 67 Japan In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 68 Japan In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 69 Japan In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 70 Japan In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 71 China In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 72 China In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 73 China In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 74 China In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 75 India In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 76 India In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 77 India In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 78 India In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 79 South Korea In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 80 South Korea In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 81 South Korea In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 82 South Korea In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 83 Australia In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 84 Australia In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 85 Australia In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 86 Australia In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 87 Thailand In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 88 Thailand In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 89 Thailand In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 90 Thailand In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 91 Latin America In Vivo CRO Market, By Country, 2018 - 2030 (USD Million)
  • Table 92 Latin America In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 93 Latin America In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 94 Latin America In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 95 Latin America In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 96 Brazil In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 97 Brazil In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 98 Brazil In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 99 Brazil In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 100 Argentina In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 101 Argentina In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 102 Argentina In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 103 Argentina In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 104 Middle East and Africa In Vivo CRO Market, By Country, 2018 - 2030 (USD Million)
  • Table 105 Middle East and Africa In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 106 Middle East and Africa In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 107 Middle East and Africa In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 108 Middle East and Africa In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 109 South Africa In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 110 South Africa In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 111 South Africa In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 112 South Africa In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 116 Saudi Arabia In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 117 UAE In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 118 UAE In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 119 UAE In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 120 UAE In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
  • Table 121 Kuwait In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
  • Table 122 Kuwait In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
  • Table 123 Kuwait In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
  • Table 124 Kuwait In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 In Vivo CRO Market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Data Analysis Models
  • Fig. 6 Market Formulation And Validation
  • Fig. 7 Data Validating & Publishing
  • Fig. 8 Parent Market Analysis
  • Fig. 9 Service/Commodity Flow Analysis
  • Fig. 10 Value-Chain-Based Sizing & Forecasting
  • Fig. 11 QFD Model Sizing & Forecasting
  • Fig. 12 Market formulation & validation
  • Fig. 13 Market Snapshot
  • Fig. 14 Segment Snapshot
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Parent market analysis, 2024 (USD Million)
  • Fig. 17 Ancillary market outlook, 2024 (USD Million)
  • Fig. 18 In vivo CRO market dynamics
  • Fig. 19 FDA expedited approval pathway
  • Fig. 20 Porter's Five Forces Analysis
  • Fig. 21 SWOT analysis by factor (political, legal, economic, social, environmental, and technological)
  • Fig. 22 Companies With Affected Trials, By Size
  • Fig. 23 Affected Trials, By Study Phase
  • Fig. 24 Clinical trial scenario (As of January 2023/24)
  • Fig. 25 In vivo CRO market model type outlook: Segment dashboard
  • Fig. 26 In vivo CRO Market, by model type segment: Market Share, 2024 & 2030
  • Fig. 27 Rodent-based market, 2018 - 2030 (USD Million)
  • Fig. 28 Rat model market, 2018 - 2030 (USD Million)
  • Fig. 29 Mice model market, 2018 - 2030 (USD Million)
  • Fig. 30 Others market, 2018 - 2030 (USD Million)
  • Fig. 31 Non rodent-based market, 2018 - 2030 (USD Million)
  • Fig. 32 In vivo CRO market, by indication segment: Market Share, 2024 & 2030
  • Fig. 33 Autoimmune/inflammatory conditions market, 2018 - 2030 (USD Million)
  • Fig. 34 Rheumatoid arthritis market, 2018 - 2030 (USD Million)
  • Fig. 35 Multiple sclerosis market, 2018 - 2030 (USD Million)
  • Fig. 36 Osteoarthritis market, 2018 - 2030 (USD Million)
  • Fig. 37 Irritable bowel syndrome market, 2018 - 2030 (USD Million)
  • Fig. 38 Others market, 2018 - 2030 (USD Million)
  • Fig. 39 Pain management market, 2018 - 2030 (USD Million)
  • Fig. 40 Chronic pain market, 2018 - 2030 (USD Million)
  • Fig. 41 Acute pain market, 2018 - 2030 (USD Million)
  • Fig. 42 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 43 Blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 44 Solid tumor market, 2018 - 2030 (USD Million)
  • Fig. 45 Syngeneic model market, 2018 - 2030 (USD Million)
  • Fig. 46 Patient derived xenograft market, 2018 - 2030 (USD Million)
  • Fig. 47 Xenograft market, 2018 - 2030 (USD Million)
  • Fig. 48 Others oncology types market, 2018 - 2030 (USD Million)
  • Fig. 49 CNS conditions market, 2018 - 2030 (USD Million)
  • Fig. 50 Epilepsy market, 2018 - 2030 (USD Million)
  • Fig. 51 The Parkinson's development pipeline by phase
  • Fig. 52 Parkinson's disease market, 2018 - 2030 (USD Million)
  • Fig. 53 Huntington's disease market, 2018 - 2030 (USD Million)
  • Fig. 54 Stroke market, 2018 - 2030 (USD Million)
  • Fig. 55 Traumatic brain injury market, 2018 - 2030 (USD Million)
  • Fig. 56 Amyotrophic Lateral Sclerosis (ALS) market, 2018 - 2030 (USD Million)
  • Fig. 57 Muscle regeneration market, 2018 - 2030 (USD Million)
  • Fig. 58 Alzheimer's development pipeline, by phase
  • Fig. 59 Alzheimer's development pipeline, by disease severity
  • Fig. 60 Alzheimer's disease market, 2018 - 2030 (USD Million)
  • Fig. 61 Spinal muscular atrophy market, 2018 - 2030 (USD Million)
  • Fig. 62 Muscular dystrophy market, 2018 - 2030 (USD Million)
  • Fig. 63 Neurodevelopment disorders market, 2018 - 2030 (USD Million)
  • Fig. 64 Diabetes market, 2018 - 2030 (USD Million)
  • Fig. 65 Obesity market, 2018 - 2030 (USD Million)
  • Fig. 66 Others market, 2018 - 2030 (USD Million)
  • Fig. 67 In Vivo CRO Market Modality Type Outlook:Segment dashboard
  • Fig. 68 In Vivo CRO Market, By Modality Type Segment: Market Share, 2024 & 2030
  • Fig. 69 Large molecule market, 2018 - 2030 (USD Million)
  • Fig. 70 Cell and gene therapies market, 2018 - 2030 (USD Million)
  • Fig. 71 CAR-T cell therapies market, 2018 - 2030 (USD Million)
  • Fig. 72 CAR-NK cell therapies market, 2018 - 2030 (USD Million)
  • Fig. 73 TCR-T cell therapy market, 2018 - 2030 (USD Million)
  • Fig. 74 Other market, 2018 - 2030 (USD Million)
  • Fig. 75 RNA therapy market, 2018 - 2030 (USD Million)
  • Fig. 76 Others market, 2018 - 2030 (USD Million)
  • Fig. 77 Small molecules market, 2018 - 2030 (USD Million)
  • Fig. 78 In Vivo CRO Market GLP Type Outlook: Segment dashboard
  • Fig. 79 In Vivo CRO Market, By GLP Type Segment: Market Share, 2024 & 2030
  • Fig. 80 GLP Toxicology Market, 2018 - 2030 (USD Million)
  • Fig. 81 Non-GLP Market, 2018 - 2030 (USD Million)
  • Fig. 82 In vivo CRO market revenue, by region, 2024 & 2030 (USD Million)
  • Fig. 83 Regional market share analysis, 2024 & 2030
  • Fig. 84 Regional marketplace: key takeaways
  • Fig. 85 Regional marketplace: key takeaways
  • Fig. 86 North America in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 U.S. in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 Canada in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 Mexico in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Europe in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 Germany in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Key country dynamics
  • Fig. 97 UK in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 France in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Key country dynamics
  • Fig. 101 Spain in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Key country dynamics
  • Fig. 103 Italy in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 104 Key country dynamics
  • Fig. 105 Denmark in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Key country dynamics
  • Fig. 107 Sweden in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 Key country dynamics
  • Fig. 109 Italy in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 Asia Pacific in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Key Country Dynamics
  • Fig. 112 Japan in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Key Country Dynamics
  • Fig. 114 China In vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 115 Key Country Dynamics
  • Fig. 116 India in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 117 Key Country Dynamics
  • Fig. 118 Australia in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 Key Country Dynamics
  • Fig. 120 South Korea in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 121 Key country dynamic
  • Fig. 122 Thailand in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 123 Latin America in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 124 Key country dynamics
  • Fig. 125 Brazil in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 126 Key country dynamics
  • Fig. 127 Argentina in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 128 MEA in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 129 Key country dynamics
  • Fig. 130 South Africa in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 131 Key country dynamics
  • Fig. 132 Saudi Arabia in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 133 Key country dynamics
  • Fig. 134 UAE in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 135 Key country dynamics
  • Fig. 136 Kuwait in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 137 Key company categorization
  • Fig. 138 Company market position analysis
  • Fig. 139 In Vivo CRO Market Share Analysis, 2023
  • Fig. 140 Strategic framework